Amsterdam Neuroscience

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab

Hogenboom, L., Schoof, L. G., Gelissen, L. M. Y., Mostert, J., van Rooij, L., Hoitsma, E., van Munster, C. E. P., van Eijk, J., Kalkers, N. F., Adriani, K. S., Vennegoor, A., Arts, I. M. P., Mensing, L., Eurelings, M., de Gans, K., Gerlach, O., Hoogervorst, E. L. J., Kloosterziel, M. E., Kragt, J. J. & Portier, R. P. & 14 others, Smets, I., van Geel, B. M., Nielsen, J., Roosendaal, C. M., Piet, J. R., Zeinstra, E., Groeneveld, O. N., van Oosten, B. W., de Jong, B. A., Uitdehaag, B. M. J., Strijbis, E. M. M., Lissenberg-Witte, B. I., Killestein, J. & van Kempen, Z. L. E., 1 Jul 2026, In: European Journal of Neurology. 33, 7, e70695.

Research output: Contribution to Journal › Article › Academic › peer-review

Author response to letter to the editor

Gelissen, L. M. Y., Hogenboom, L. & van Kempen, Z. L. E., 15 Jan 2026, In: Journal of the Neurological Sciences. 480, 125704.

Research output: Contribution to Journal › Comment / Letter to the editor › Academic

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis

Gelissen, L. M. Y., van den Berg, S. P. H., Toorop, A. A., Wijburg, M. T., Tallantyre, E. C., Derksen, N. I. L., Loeff, F. C., Killestein, J. & NEXT-MS study group, Jan 2026, In: Frontiers in immunology. 17, p. 1796273 1796273.

Research output: Contribution to Journal › Article › Academic › peer-review